Bronstein, Gewirtz & Grossman, LLC Initiates Investigation into Liquidia Technologies, Inc. for Potential Investor Claims

NEW YORK, Sept. 02, 2024 (GLOBE NEWSWIRE) - The law firm of Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Liquidia Technologies, Inc. LQDA on behalf of investors who have purchased shares in the company. The firm is actively seeking out purchasers of Liquidia's securities to come forward with their claims of alleged corporate misdoings.

About Liquidia Technologies, Inc.

Liquidia Corporation, operating with the ticker LQDA, is a biopharmaceutical company based in Morrisville, North Carolina. The company emphasizes the development, manufacturing, and marketing of innovative products that aim to meet the unmet medical needs of patients in the United States. As a player in the biopharmaceutical sector, Liquidia focuses on creating novel solutions to improve patient outcomes.

Call to Investors

The investigation by Bronstein, Gewirtz & Grossman, LLC calls on investors who have purchased securities from Liquidia Technologies, Inc. to step forward. The firm urges investors to seek compensation for potential losses due to supposed wrongdoings and misrepresentations by the company. This notice serves as an attorney advertisement, encouraging shareholders to explore their legal rights and options.

For investors who have a stake in Liquidia Corporation, the call to participate in this investigation presents an opportunity to address concerns regarding their investments. The law firm signals its readiness to assist such shareholders in determining if they have been affected by any unlawful business practices that may have impacted the value of their investments in LQDA.

investigation, biopharmaceutical, compensation